Evidence-Based Approach of Biologic Therapy in Bronchial Asthma
Abstract
:1. Introduction
2. Pathophysiology of Asthma
3. Selecting Biologic Therapy in Bronchial Asthma
4. Various Biologic Agents
4.1. Omalizumab (Anti-IgE)
4.2. Reslizumab (Anti-IL5)
4.3. Benralizumab (Anti-IL5)
4.4. Mepolizumab (Anti-IL5)
4.5. Dupilumab (Anti-IL4/IL13)
4.6. Tezepelumab (Anti-Thymic Stromal Lymphopoietin)
Drug | Mechanism of Action | Route of Administration | Indication | Contraindication |
---|---|---|---|---|
Omalizumab | Binds IgE to prevent binding to high-affinity IgE receptors (FcεRI) on dendritic, basophils, and mast cells | Subcutaneous | Treatment of moderate to severe persistent allergic asthma for patients aged ≥6 years with positive skin test or in vitro reactivity to a perennial aeroallergen and uncontrolled on inhaled corticosteroids | Known hypersensitivity reaction |
Reslizumab | Binds to IL-5 | Intravenous | Add on maintenance treatment of patients with severe asthma aged ≥18 with an eosinophilic subtype | Known hypersensitivity reaction |
Benralizumab | Binds IL-5R on eosinophils inducing natural killer cell-mediated eosinophil apoptosis | Subcutaneous | Add on maintenance treatment of patients with severe asthma aged ≥12 and with an eosinophilic phenotype | Known hypersensitivity reaction |
Mepolizumab | Binds to IL-5 | Subcutaneous | Add on maintenance treatment of patients with severe asthma aged ≥6 with an eosinophilic phenotype | Known hypersensitivity reaction |
Dupilumab | Binds to IL-4R alpha inhibiting IL-4 and IL-13 signaling | Subcutaneous | Add on maintenance treatment of patients aged ≥6 with moderate to severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid-dependent asthma | Known hypersensitivity reaction |
Tezepelumab | Binds to thymic stromal lymphopoietin (TSLP) | Subcutaneous | Add on maintenance treatment of adult and pediatric patients ≥ 12 with severe asthma | Known hypersensitivity reaction |
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Reddel, H.K.; Bacharier, L.B.; Bateman, E.D.; Boulet, L.-P.; Brightling, C.; Brusselle, G.; Buhl, R.; Drazen, J.M.; Duijts, L.; FitzGerald, J.M.; et al. Global Initiative for Asthma—GINA. 2022. Available online: https://ginasthma.org/wp-content/uploads/2022/07/GINA-Main-Report-2022-FINAL-22-07-01-WMS.pdf (accessed on 1 January 2022).
- Alberto, P.; Brightling, C.; Pedersen, S.E.; Reddel, H.K. Asthma. Lancet 2017, 391, 783–800. [Google Scholar] [CrossRef]
- Holgate, S.T. Innate and Adaptive Immune Responses in Asthma. Nat. Med. 2012, 18, 673–683. [Google Scholar] [CrossRef] [PubMed]
- Holgate, S.T.; Wenzel, S.; Postma, D.S.; Weiss, S.T.; Renz, H.; Sly, P.D. Asthma. Nat. Rev. Dis. Prim. 2015, 1, 15025. [Google Scholar] [CrossRef] [PubMed]
- Wan, X.C.; Woodruff, P.G. Biomarkers in Severe Asthma. Immunol. Allergy Clin. N. Am. 2016, 36, 547–557. [Google Scholar] [CrossRef] [PubMed]
- Habib, N.; Pasha, M.A.; Tang, D.D. Current Understanding of Asthma Pathogenesis and Biomarkers. Cells 2022, 11, 2764. [Google Scholar] [CrossRef]
- Ogulur, I.; Pat, Y.; Ardicli, O.; Barletta, E.; Cevhertas, L.; Fernandez-Santamaria, R.; Huang, M.; Bel Imam, M.; Koch, J.; Ma, S.; et al. Advances and highlights in biomarkers of allergic diseases. Allergy 2021, 76, 3659–3686. [Google Scholar] [CrossRef]
- Gamble, J.; Stevenson, M.; McClean, E.; Heaney, L.G. The Prevalence of Nonadherence in Difficult Asthma. Am. J. Respir. Crit. Care Med. 2009, 180, 817–822. [Google Scholar] [CrossRef]
- Charriot, J.; Maravic, M.; Huguet, M.; Vachier, I.; Suehs, C.; Bourdin, A. ‘Real-Life’ Management of Patients with Severe Asthma in the Biologics Era: Can We Do Better? World Allergy Organ. J. 2021, 14, 100528. [Google Scholar] [CrossRef]
- Bikov, A.; Oğuzülgen, I.K.; Baiardini, I.; Contoli, M.; Emelyanov, A.; Fassio, O.; Ivancevich, J.C.; Kaidashev, I.; Kowal, K.; Labor, M.; et al. Beliefs and Preferences Regarding Biological Treatments for Severe Asthma. World Allergy Organ. J. 2020, 13, 100441. [Google Scholar] [CrossRef]
- Olin, J.T.; Wechsler, M.E. Asthma: Pathogenesis and Novel Drugs for Treatment. BMJ 2014, 349, g5517. [Google Scholar] [CrossRef] [Green Version]
- Bender, B.; Oppenheimer, J.; George, M.; Brown, R.; Patel, A.; Hill, T.; Boe, A.; Herrera, E.M.; Dotiwala, Z.; Casciano, J.; et al. Assessment of Real-World Escalation to Biologics in US Patients with Asthma. J. Allergy Clin. Immunol. Pract. 2022, 10, 2941–2948. [Google Scholar] [CrossRef]
- Mavissakalian, M.; Brady, S. The Current State of Biologic Therapies for Treatment of Refractory Asthma. Clin. Rev. Allergy Immunol. 2020, 59, 195–207. [Google Scholar] [CrossRef]
- Cloutier, M.M.; Baptist, A.P.; Blake, K.V.; Brooks, E.G.; Bryant-Stephens, T.; DiMango, E.; Dixon, A.E.; Elward, K.S.; Hartert, T.; Krishnan, J.A.; et al. 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. J. Allergy Clin. Immunol. 2020, 146, 1217–1270. [Google Scholar] [CrossRef]
- Busse, W.W. Biological Treatments for Severe Asthma: A Major Advance in Asthma Care. Allergol. Int. 2019, 68, 158–166. [Google Scholar] [CrossRef]
- Whittington, M.D.; McQueen, R.B.; Ollendorf, D.A.; Tice, J.A.; Chapman, R.H.; Pearson, S.D.; Campbell, J.D. Assessing the Value of Mepolizumab for Severe Eosinophilic Asthma: A Cost-Effectiveness Analysis. Ann. Allergy Asthma Immunol. 2017, 118, 220–225. [Google Scholar] [CrossRef]
- Jeffery, M.M.; Inselman, J.W.; Maddux, J.T.; Lam, R.W.; Shah, N.D.; Rank, M.A. Asthma Patients Who Stop Asthma Biologics Have a Similar Risk of Asthma Exacerbations as Those Who Continue Asthma Biologics. J. Allergy Clin. Immunol. Pract. 2021, 9, 2742–2750. [Google Scholar] [CrossRef]
- Ali, N.; Chen, S.; Tran, T.N.; Cook, W.; Altraja, A.; AB Bourdin, A.; Sheu, C.-C.; Tsai, M.J.; Hoyte, F.C.; Quinton, A.R.; et al. Clinical Outcomes in Patients with Severe Asthma Who Had or Had Not Initiated Biologic Therapy: Results from the Clear Study. Chest 2022, 162, A28–A32. [Google Scholar] [CrossRef]
- Ali, N.; Chen, S.; Tran, T.N.; Cook, W.; Altraja, A.; AB Bourdin, A.; Sheu, C.-C.; Tsai, M.J.; Hoyte, F.C.; Quinton, A.R.; et al. Clinical Outcomes and Emergency Health Care Utilization in Patients with Severe Asthma Who Continued, Switched, or Stopped Biologic Therapy: Results from the Clear Study. Chest 2022, 162, A23–A27. [Google Scholar] [CrossRef]
- Opina, M.T.; Moore, W.C. Phenotype-Driven Therapeutics in Severe Asthma. Curr. Allergy Asthma Rep. 2017, 17, 10. [Google Scholar] [CrossRef]
- Casale, T.B.; Chipps, B.E.; Rosén, K.; Trzaskoma, B.; Haselkorn, T.; Omachi, T.A.; Greenberg, S.; Hanania, N.A. Response to Omalizumab Using Patient Enrichment Criteria from Trials of Novel Biologics in Asthma. Allergy 2017, 73, 490–497. [Google Scholar] [CrossRef] [Green Version]
- Kardas, G.; Kuna, P.; Panek, M. Biological Therapies of Severe Asthma and Their Possible Effects on Airway Remodeling. Front. Immunol. 2020, 11, 1134. [Google Scholar] [CrossRef] [PubMed]
- McCracken, J.L.; Tripple, J.W.; Calhoun, W.J. Biologic Therapy in the Management of Asthma. Curr. Opin. Allergy Clin. Immunol. 2016, 16, 375–382. [Google Scholar] [CrossRef] [PubMed]
- Normansell, R.; Walker, S.; Milan, S.J.; Walters, E.H.; Nair, P. Omalizumab for Asthma in Adults and Children. Cochrane Database Syst. Rev. 2014, 1, CD003559. [Google Scholar] [CrossRef]
- Humbert, M.; Beasley, R.; Ayres, J.; Slavin, R.; Hébert, J.; Bousquet, J.; Beeh, K.M.; Ramos, S.; Canonica, G.W.; Hedgecock, S.; et al. Benefits of Omalizumab as Add-on Therapy in Patients with Severe Persistent Asthma Who Are Inadequately Controlled despite Best Available Therapy (Gina 2002 Step 4 Treatment): Innovate. Allergy 2005, 60, 309–316. [Google Scholar] [CrossRef] [PubMed]
- Hanania, N.A.; Alpan, O.; Hamilos, D.L.; Condemi, J.J.; Reyes-Rivera, I.; Zhu, J.; Rosen, K.E.; Eisner, M.D.; Wong, D.A.; Busse, W. Omalizumab in Severe Allergic Asthma Inadequately Controlled with Standard Therapy. Ann. Intern. Med. 2011, 154, 573. [Google Scholar] [CrossRef] [PubMed]
- Casale, T.B.; Luskin, A.T.; Busse, W.; Zeiger, R.S.; Trzaskoma, B.; Yang, M.; Griffin, N.M.; Chipps, B.E. Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence from Prospero, a Prospective Real-World Study. J. Allergy Clin. Immunol. Pract. 2019, 7, 156–164. [Google Scholar] [CrossRef]
- McGregor, M.C.; Krings, J.G.; Nair, P.; Castro, M. Role of Biologics in Asthma. Am. J. Respir. Crit. Care Med. 2019, 199, 433–445. [Google Scholar] [CrossRef]
- Hayashi, H.; Fukutomi, Y.; Mitsui, C.; Kajiwara, K.; Watai, K.; Kamide, Y.; Nakamura, Y.; Hamada, Y.; Tomita, Y.; Sekiya, K.; et al. Omalizumab for Aspirin Hypersensitivity and Leukotriene Overproduction in Aspirin-Exacerbated Respiratory Disease. A Randomized Controlled Trial. Am. J. Respir. Crit. Care Med. 2020, 201, 1488–1498. [Google Scholar] [CrossRef] [Green Version]
- Chan, S.; Cornelius, V.; Cro, S.; Harper, J.I.; Lack, G. Treatment Effect of Omalizumab on Severe Pediatric Atopic Dermatitis. JAMA Pediatr. 2020, 174, 29–37. [Google Scholar] [CrossRef]
- Kroes, J.A.; Zielhuis, S.W.; van der Meer, A.-N.; de Jong, K.; van Roon, E.N.; ten Brinke, A. Optimizing Omalizumab Dosing in Severe Asthma—The Exploration of Therapeutic Drug Monitoring. J. Allergy Clin. Immunol. Pract. 2021, 9, 1408–1410. [Google Scholar] [CrossRef]
- Iribarren, C.; Rahmaoui, A.; Long, A.A.; Szefler, S.J.; Bradley, M.S.; Carrigan, G.; Eisner, M.D.; Chen, H.; Omachi, T.A.; Farkouh, M.E.; et al. Cardiovascular and Cerebrovascular Events among Patients Receiving Omalizumab: Results from Excels, a Prospective Cohort Study in Moderate to Severe Asthma. J. Allergy Clin. Immunol. 2017, 139, 1489–1495. [Google Scholar] [CrossRef] [Green Version]
- CINQAIR. Prescribing Information. Teva Respiratory. February 2020. Available online: https://www.cinqair.com/globalassets/cinqair/prescribinginformation.pdf (accessed on 1 January 2022).
- Hom, S.; Pisano, M. Reslizumab (Cinqair): An Interleukin-5 Antagonist for Severe Asthma of the Eosinophilic Phenotype. Pharm. Ther. 2017, 42, 564–568. Available online: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5565129/ (accessed on 10 January 2022).
- Bjermer, L.; Lemiere, C.; Maspero, J.; Weiss, S.; Zangrilli, J.; Germinaro, M. Reslizumab for Inadequately Controlled Asthma with Elevated Blood Eosinophil Levels. Chest 2016, 150, 789–798. [Google Scholar] [CrossRef] [Green Version]
- CTG Labs—NCBI. A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients with Eosinophilic Asthma; Teva Branded Pharmaceutical Products R&D, Inc.: West Chester, PA, USA, 2021. Available online: https://beta.clinicaltrials.gov/study/NCT01285323?tab=results#publications (accessed on 12 January 2022).
- CTG Labs—NCBI. A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 Mg/Kg) as Treatment for Patients (12–75 Years of Age) with Eosinophilic Asthma; Teva Branded Pharmaceutical Products R&D, Inc.: West Chester, PA, USA, 2016. Available online: https://beta.clinicaltrials.gov/study/NCT01270464 (accessed on 10 January 2022).
- Corren, J.; Weinstein, S.; Janka, L.; Zangrilli, J.; Garin, M. Phase 3 Study of Reslizumab in Patients with Poorly Controlled Asthma. Chest 2016, 150, 799–810. [Google Scholar] [CrossRef] [Green Version]
- Bleecker, E.R.; FitzGerald, J.M.; Chanez, P.; Papi, A.; Weinstein, S.F.; Barker, P.; Sproule, S.; Gilmartin, G.; Aurivillius, M.; Werkström, V.; et al. Efficacy and Safety of Benralizumab for Patients with Severe Asthma Uncontrolled with High-Dosage Inhaled Corticosteroids and Long-Acting β2-Agonists (SIROCCO): A Randomised, Multicentre, Placebo-Controlled Phase 3 Trial. Lancet 2016, 388, 2115–2127. [Google Scholar] [CrossRef]
- FitzGerald, J.M.; Bleecker, E.R.; Nair, P.; Korn, S.; Ohta, K.; Lommatzsch, M.; Ferguson, G.T.; Busse, W.W.; Barker, P.; Sproule, S.; et al. Benralizumab, an Anti-Interleukin-5 Receptor α Monoclonal Antibody, as Add-on Treatment for Patients with Severe, Uncontrolled, Eosinophilic Asthma (Calima): A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial. Lancet 2016, 388, 2128–2141. [Google Scholar] [CrossRef]
- Nair, P.; Wenzel, S.; Rabe, K.F.; Bourdin, A.; Lugogo, N.L.; Kuna, P.; Barker, P.; Sproule, S.; Ponnarambil, S.; Goldman, M. Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma. N. Engl. J. Med. 2017, 376, 2448–2458. [Google Scholar] [CrossRef]
- Carstens, D.D.; Genofre, E.H.; Young, J.A.; Yang, D.; Mu, F.; Cook, E.E.; Betts, K.A.; Chung, Y. Long-Term Real-World Effectiveness of Benralizumab in Patients with Severe Eosinophilic Asthma: Results from the Zephyr 2 Study. Chest 2022, 162, A7. [Google Scholar] [CrossRef]
- Fasenra; AstraZeneca Pharmaceuticals. FASENRA® (Benralizumab) for Severe Eosinophilic Asthma|for Hcps. 2022. Available online: https://www.fasenrahcp.com/ (accessed on 10 January 2023).
- Walsh, G.M. Mepolizumab-Based Therapy in Asthma. Curr. Opin. Allergy Clin. Immunol. 2015, 15, 392–396. [Google Scholar] [CrossRef]
- Nair, P.; Pizzichini, M.M.M.; Kjarsgaard, M.; Inman, M.D.; Efthimiadis, A.; Pizzichini, E.; Hargreave, F.E.; O’Byrne, P.M. Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia. N. Engl. J. Med. 2009, 360, 985–993. [Google Scholar] [CrossRef]
- Haldar, P.; Brightling, C.E.; Hargadon, B.; Gupta, S.; Monteiro, W.; Sousa, A.; Marshall, R.P.; Bradding, P.; Green, R.H.; Wardlaw, A.J.; et al. Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma. N. Engl. J. Med. 2009, 360, 973–984. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pavord, I.D.; Korn, S.; Howarth, P.; Bleecker, E.R.; Buhl, R.; Keene, O.N.; Ortega, H.; Chanez, P. Mepolizumab for Severe Eosinophilic Asthma (Dream): A Multicentre, Double-Blind, Placebo-Controlled Trial. Lancet 2012, 380, 651–659. [Google Scholar] [CrossRef] [PubMed]
- Emma, R.; Morjaria, J.B.; Fuochi, V.; Polosa, R.; Caruso, M. Mepolizumab in the Management of Severe Eosinophilic Asthma in Adults: Current Evidence and Practical Experience. Ther. Adv. Respir. Dis. 2018, 12, 1–12. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ortega, H.G.; Liu, M.C.; Pavord, I.D.; Brusselle, G.G.; FitzGerald, J.M.; Chetta, A.; Humbert, M.; Katz, L.E.; Keene, O.N.; Yancey, S.W.; et al. Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma. N. Engl. J. Med. 2014, 371, 1198–1207. [Google Scholar] [CrossRef] [Green Version]
- Bel, E.H.; Wenzel, S.E.; Thompson, P.J.; Prazma, C.M.; Keene, O.N.; Yancey, S.W.; Ortega, H.G.; Pavord, I.D. Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma. N. Engl. J. Med. 2014, 371, 1189–1197. [Google Scholar] [CrossRef]
- Ortega, H.G.; Yancey, S.W.; Mayer, B.; Gunsoy, N.B.; Keene, O.N.; Bleecker, E.R.; Brightling, C.E.; Pavord, I.D. Severe Eosinophilic Asthma Treated with Mepolizumab Stratified by Baseline Eosinophil Thresholds: A Secondary Analysis of the Dream and Mensa Studies. Lancet Respir. Med. 2016, 4, 549–556. [Google Scholar] [CrossRef]
- Thompson, C.A. Mepolizumab Approved as Add-on Long-Term Therapy for Severe Asthma. Am. J. Health-Syst. Pharm. 2015, 72, 2125. [Google Scholar] [CrossRef]
- GlaxoSmithKline LLC. Prescribing Information-Gskpro. Nucala (Mepolizumab). Available online: https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Benlysta/pdf/BENLYSTA-PI-MG-IFU.PDF (accessed on 12 March 2023).
- Castro, M.; Corren, J.; Pavord, I.D.; Maspero, J.; Wenzel, S.; Rabe, K.F.; Busse, W.W.; Ford, L.; Sher, L.; FitzGerald, J.M.; et al. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N. Engl. J. Med. 2018, 378, 2486–2496. [Google Scholar] [CrossRef]
- Rathinam, K.K.; Abraham, J.J.; Vijayakumar, T.M. Dupilumab in the Treatment of Moderate to Severe Asthma: An Evidence-Based Review. Curr. Ther. Res. 2019, 91, 45–51. [Google Scholar] [CrossRef]
- Wenzel, S.; Castro, M.; Corren, J.; Maspero, J.; Wang, L.; Zhang, B.; Pirozzi, G.; Sutherland, E.R.; Evans, R.R.; Joish, V.N.; et al. Dupilumab Efficacy and Safety in Adults with Uncontrolled Persistent Asthma despite Use of Medium-to-High-Dose Inhaled Corticosteroids plus a Long-Acting Β2 Agonist: A Randomised Double-Blind Placebo-Controlled Pivotal Phase 2b Dose-Ranging Trial. Lancet 2016, 388, 31–44. [Google Scholar] [CrossRef]
- Rabe, K.F.; Nair, P.; Brusselle, G.; Maspero, J.F.; Castro, M.; Sher, L.; Zhu, H.; Hamilton, J.D.; Swanson, B.N.; Khan, A.; et al. Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma. N. Engl. J. Med. 2018, 378, 2475–2485. [Google Scholar] [CrossRef]
- Gurnell, M.; Domingo, C.C.; Rabe, K.F.; Menzies-Gow, A.; Price, D.B.; Brusselle, G.G.; Wechsler, M.E.; Xia, C.; Pandit-Abid, N.; Gall, R.; et al. Dupilumab Treatment Leads to Sustained Reductions in Oral Corticosteroid Use in Patients with Oral Corticosteroid-Dependent Severe Asthma. Chest 2022, 162, A1909–A1913. [Google Scholar] [CrossRef]
- Bacharier, L.B.; Maspero, J.F.; Katelaris, C.H.; Fiocchi, A.G.; Gagnon, R.; de Mir, I.; Jain, N.; Sher, L.D.; Mao, X.; Liu, D.; et al. Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma. N. Engl. J. Med. 2021, 385, 2230–2240. [Google Scholar] [CrossRef]
- Simpson, E.L.; Bieber, T.; Guttman-Yassky, E.; Beck, L.A.; Blauvelt, A.; Cork, M.J.; Silverberg, J.I.; Deleuran, M.; Kataoka, Y.; Lacour, J.P.; et al. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. N. Engl. J. Med. 2016, 375, 2335–2348. [Google Scholar] [CrossRef]
- Bourdin, A.; Virchow, J.C.; Papi, A.; Lugogo, N.L.; Bardin, P.; Antila, M.; Halpin, D.M.; Daizadeh, N.; Djandji, M.; Ortiz, B.; et al. Dupilumab Efficacy in Subgroups of Type 2 Asthma with High-Dose Inhaled Corticosteroids at Baseline. Respir. Med. 2022, 202, 106938. [Google Scholar] [CrossRef]
- Corren, J.; Parnes, J.R.; Wang, L.; Mo, M.; Roseti, S.L.; Griffiths, J.M.; van der Merwe, R. Tezepelumab in Adults with Uncontrolled Asthma. N. Engl. J. Med. 2017, 377, 936–946. [Google Scholar] [CrossRef]
- Kitajima, M.; Lee, H.-C.; Nakayama, T.; Ziegler, S.F. TSLP Enhances the Function of Helper Type 2 Cells. Eur. J. Immunol. 2011, 41, 1862–1871. [Google Scholar] [CrossRef] [Green Version]
- Shikotra, A.; Choy, D.F.; Ohri, C.M.; Doran, E.; Butler, C.; Hargadon, B.; Shelley, M.; Abbas, A.R.; Austin, C.D.; Jackman, J.; et al. Increased Expression of Immunoreactive Thymic Stromal Lymphopoietin in Patients with Severe Asthma. J. Allergy Clin. Immunol. 2012, 129, 104–111. [Google Scholar] [CrossRef]
- Gauvreau, G.M.; O’Byrne, P.M.; Boulet, L.P.; Wang, Y.; Cockcroft, D.; Bigler, J.; FitzGerald, J.M.; Boedigheimer, M.; Davis, B.E.; Dias, C.; et al. Effects of an Anti-TSLP Antibody on Allergen-Induced Asthmatic Responses. N. Engl. J. Med. 2014, 370, 2102–2110. [Google Scholar] [CrossRef]
- Ying, S.; O’Connor, B.; Ratoff, J.; Meng, Q.; Mallett, K.; Cousins, D.; Robinson, D.; Zhang, G.; Zhao, J.; Lee, T.H.; et al. Thymic Stromal Lymphopoietin Expression Is Increased in Asthmatic Airways and Correlates with Expression of th2-Attracting Chemokines and Disease Severity. J. Immunol. 2005, 174, 8183–8190. [Google Scholar] [CrossRef] [Green Version]
- Tezspire; AstraZeneca. Dosing and Administration|TEZSPIRE® (Tezepelumab-Ekko) for Hcps. September 2022. Available online: https://www.tezspirehcp.com/dosing-and-administration.html (accessed on 10 January 2023).
- Pham, T.-H.; Ren, P.; Parnes, J.R.; Griffiths, J.M. Tezepelumab Reduces Multiple Key Inflammatory Biomarkers in Patients with Severe, Uncontrolled Asthma in the Phase 2B Pathway Study. B21. Severe Asthma: Clinical and Mechanistic Studies. 2019. Available online: https://www.atsjournals.org/doi/10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A2677 (accessed on 10 January 2022).
- Upham, J.W.; Jurak, L.M. How Do Biologicals and Other Novel Therapies Effect Clinically Used Biomarkers in Severe Asthma? Clin. Exp. Allergy 2020, 50, 994–1006. [Google Scholar] [CrossRef] [PubMed]
- Menzies-Gow, A.; Colice, G.; Griffiths, J.M.; Almqvist, G.; Ponnarambil, S.; Kaur, P.; Ruberto, G.; Bowen, K.; Hellqvist, Å.; Mo, M.; et al. Navigator: A Phase 3 Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma. Respir. Res. 2020, 21, 266. [Google Scholar] [CrossRef] [PubMed]
- Kraft, M.; Colice, G.L.; Ambrose, C.; Cook, W.; Hunter, G.; Molfino, E.A.; Martin, N.; Roseti, S.L. Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma Grouped by Number of Additional Asthma Controller Medications: Results from the Phase 3 Navigator Study. Chest 2022, 162, A11–A12. [Google Scholar] [CrossRef]
- AstraZeneca. Update on Source Phase III Trial for Tezepelumab in Patients with Severe, Oral Corticosteroid-Dependent Asthma. 2020. Available online: https://www.astrazeneca.com/media-centre/press-releases/2020/update-on-source-phase-iii-trial-for-tezepelumab-in-patients-with-severe-oral-corticosteroid-dependent-asthma.html (accessed on 13 January 2023).
- Diver, S.; Khalfaoui, L.; Emson, C.; Wenzel, S.E.; Menzies-Gow, A.; Wechsler, M.E.; Johnston, J.; Molfino, N.; Parnes, J.R.; Megally, A.; et al. Effect of Tezepelumab on Airway Inflammatory Cells, Remodelling, and Hyperresponsiveness in Patients with Moderate-to-Severe Uncontrolled Asthma (CASCADE): A Double-Blind, Randomised, Placebo-Controlled, Phase 2 Trial. Lancet Respir. Med. 2021, 9, 1299–1312. [Google Scholar] [CrossRef]
- Parnes, J.R.; Sullivan, J.T.; Chen, L.; Dias, C. Pharmacokinetics, Safety, and Tolerability of Tezepelumab (Amg 157) in Healthy and Atopic Dermatitis Adult Subjects. Clin. Pharmacol. Ther. 2019, 106, 441–449. [Google Scholar] [CrossRef] [Green Version]
- Sakamoto, K.; Matsuki, S.; Irie, S.; Uchida, N.; Hayashi, N.; Horiuchi, M.; Ren, S. A Phase 1, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Subcutaneous Tezepelumab in Healthy Japanese Men. Clin. Pharmacol. Drug Dev. 2020, 9, 833–840. [Google Scholar] [CrossRef] [Green Version]
- Zheng, Y.; Abuqayyas, L.; Megally, A.; Fuhr, R.; Sałapa, K.; Downie, J.; Colice, G. Tezepelumab Pharmacokinetics, Safety, and Tolerability after Administration via Vial-and-Syringe, Accessorized Prefilled Syringe, or Autoinjector: A Randomized Trial in Healthy Volunteers. Clin. Ther. 2021, 43, 142–155. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Liaqat, A.; Mason, M.; Foster, B.; Gregory, G.; Patel, A.; Barlas, A.; Kulkarni, S.; Basso, R.; Patak, P.; Liaqat, H.; et al. Evidence-Based Approach of Biologic Therapy in Bronchial Asthma. J. Clin. Med. 2023, 12, 4321. https://doi.org/10.3390/jcm12134321
Liaqat A, Mason M, Foster B, Gregory G, Patel A, Barlas A, Kulkarni S, Basso R, Patak P, Liaqat H, et al. Evidence-Based Approach of Biologic Therapy in Bronchial Asthma. Journal of Clinical Medicine. 2023; 12(13):4321. https://doi.org/10.3390/jcm12134321
Chicago/Turabian StyleLiaqat, Adnan, Mathew Mason, Brian Foster, Grant Gregory, Avani Patel, Aisha Barlas, Sagar Kulkarni, Rafaela Basso, Pooja Patak, Hamza Liaqat, and et al. 2023. "Evidence-Based Approach of Biologic Therapy in Bronchial Asthma" Journal of Clinical Medicine 12, no. 13: 4321. https://doi.org/10.3390/jcm12134321